 Cassava disappointed Tuesday with midstage results for its oral Alzheimers treatment and SAVA stock plummeted by a double-digit percentage. The post Cassava Plummets As Highly Desirable Alzheimers Results Dont Cut It With Investors appeared first on Investors Business Daily. 